The global
chronic lymphocytic leukemia therapeutics market is expected to create more
opportunities in oncology due to promising pipeline and positive clinical data
of drug candidates. The existing drugs for the treatment of chronic lymphocytic
leukemia is the be most effective treatment. The American Cancer Society, and
other regulatory bodies are supporting the chronic lymphocytic leukemia therapeutics
market by providing funding and grants. The market is being driven by different
factors such as rising awareness for the cancer treatments, high demand for
safe and effective medications, technologies advancements, and increasing
prevalence of cancer.
Chronic
lymphocytic leukemia is a type of gradually developing leukemia that affects
the development of B lymphocytes (also known as B cells). On the other hand, B
cells are specialized white blood cells, which produce immunoglobulins (also
called antibodies) under normal conditions, and help to protect the human body
against infections and diseases. In patients with chronic lymphocytic leukemia,
lymphocytes undergo a malignant change and become leukemic cells.
Request to Get the
Sample Pages at:
Ono
Pharmaceutical and Bristol-Myers Squibb are in the process of developing Opdivo
for the treatment of chronic lymphocytic leukemia. Genentech is developing
Atezolizumab, also known as MPDL 3280A, for chronic lymphocytic leukemia
therapeutics, which is in Phase II stage. Atezolizumab is a monoclonal antibody
targeting programmed cell death-1 ligand 1 (PD-L1). PD-L1 plays an important
role in suppressing the immune system triggered by the cancer. PD-L1 acts by
reducing the proliferation of antigen-specific CD8+ T-cells and controlling the
accumulation of foreign antigen-specific T-cells.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=chronic-lymphocytic-leukemia-therapeutics-market
The chronic
lymphocytic leukemia is more prevalent in North America, making the
region to be the largest revenue contributor, globally. The U.S. contributed
the largest revenue to the North American market in year 2016, and it is
expected to remain the largest market across the globe, during the forecast
period.
Some of the
key players operating in the chronic lymphocytic leukemia therapeutics market
are GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Biogen
Inc., AbbVie, Inc., Teva Pharmaceuticals Limited, Gilead Sciences, Inc.,
Novartis AG, and Johnson & Johnson.
